# A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

> **NCT05355402** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 154 (actual)

## Conditions studied

- Hypertriglyceridemia
- Atherosclerotic Cardiovascular Disease
- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Olezarsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05355402
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-03-22
- **Final completion:** 2023-12-21
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355402, "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05355402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*